Lundbeck's former head of North America appointed CEO of Capsida Biotherapeutics

Peter Anastasiou, who has spearheaded Danish pharmaceutical firm Lundbeck's operation in the US where he oversaw the launch of migraine drug Vyepti, has revealed the next step in his career on LinkedIn. In November, he announced his departure from Lundbeck.
Going forward, Lundbeck's former head of North America, Peter Anastasiou, will be in charge of US-based biotech firm Capsida Biotherapeutics | Photo: Lundbeck / PR
Going forward, Lundbeck's former head of North America, Peter Anastasiou, will be in charge of US-based biotech firm Capsida Biotherapeutics | Photo: Lundbeck / PR
by ulrich quistgaard

Lundbeck's departing head of North America, Peter Anastasiou, now reveals his new job title in a post on social media LinkedIn.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading